Impact of Long Wavelength Ultraviolet (UVA) and Visible Light on Melanocompetent Skin
NCT00478751 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 22
Last updated 2024-04-30
Summary
* Determine the impact and the threshold of long wavelength UVA and visible light on immediate and delayed pigment production of melanocompetent individuals.
* The study basically wants to understand what types of light make us tan.
Conditions
- Healthy
Sponsors & Collaborators
- collaborator INDUSTRY
-
Henry Ford Health System
lead OTHER
Principal Investigators
-
Iltefat H. Hamzavi, M.D. · Department of Dermatology, Henry Ford Health System
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2007-05-31
- Primary Completion
- 2008-12-31
- Completion
- 2009-01-31
Countries
- United States
Study Locations
More Related Trials
-
Safety and Efficacy of Orally Administered NUV001 Nutraceutical Supplement in Sickle Cell Disease Patients
NCT05791591 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Studies in Porphyria III: Heme and Tin Mesoporphyrin in Acute Porphyrias
NCT00004396 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of the Free α-hemoglobin Pool in the Red Blood Cells : Prognostic Marker and Severity Index in Thalassemic Syndromes
NCT02855957 ·Status: COMPLETED ·Phase: NA
-
Iron Mediated Vascular Disease in Sickle Cell Anemia Patients
NCT01239901 ·Status: COMPLETED
-
Intravenous Iron in Adults With Cystic Fibrosis
NCT03632525 ·Status: COMPLETED ·Phase: PHASE4
-
Phase I Study of Tin Mesoporphyrin in Patients on Long Term Heme Therapy for Prevention of Acute Attacks of Porphyria
NCT00004397 ·Status: COMPLETED ·Phase: PHASE1
-
Cooperative Assessment of Late Effects for SCD Curative Therapies
NCT05153967 ·Status: RECRUITING
-
Evaluating People With Thalassemia: The Thalassemia Longitudinal Cohort (TLC) Study
NCT00661804 ·Status: COMPLETED
-
Hemochromatosis--Genetic Prevalence and Penetrance
NCT00006312 ·Status: COMPLETED
-
Pharmacogenetic Study in Patients Received Iron Chelating Agent
NCT01623895 ·Status: COMPLETED
-
Low-dose Iron Supplementation and Markers of Iron Status Among Non-anemic, Iron-deficient Women
NCT02683369 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Effect of NUV001 Supplementation in Patients Suffering From Sickle Cell Disease (SCD)
NCT05789355 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Transferrin Saturation and Asthenia in Hemochromatosis
NCT03356548 ·Status: COMPLETED
-
Iron Deficiency in Female State Fair Attendees
NCT03228173 ·Status: COMPLETED
-
Far Infrared Radiation for Sickle Cell Pain Management
NCT00599482 ·Status: UNKNOWN ·Phase: PHASE1
-
Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis
NCT00000595 ·Status: COMPLETED ·Phase: PHASE2
-
Long Term Effects of Hydroxyurea Therapy in Children With Sickle Cell Disease
NCT00305175 ·Status: COMPLETED
-
The Immediate and Long-term Effects of a Novel Marine-based Iron Supplement in Adult Females
NCT07199244 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Skin and Blood Research Samples From Healthy Volunteers and Patients With Hematologic Diseases
NCT00840567 ·Status: TERMINATED ·Phase: NA
-
Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)
NCT02252159 ·Status: COMPLETED
-
Genetic Factors Affecting the Severity of Beta Thalassemia
NCT00159042 ·Status: COMPLETED
-
A Follow-up Study to Evaluate the Long-term Safety and Efficacy in Participants Who Received CS-101 Injection
NCT06717932 ·Status: ENROLLING_BY_INVITATION
-
A Stratified Sickle Event Randomized Trial (ASSERT)
NCT00102791 ·Status: TERMINATED ·Phase: PHASE3
-
A Long-term Follow-up Study in Participants Who Received CS-101
NCT06479616 ·Status: RECRUITING ·Phase: NA
-
Effect of Antioxidant Cocktail in Beta-thalassemia/Hb E Patients
NCT01597765 ·Status: COMPLETED ·Phase: NA